{
    "data": [
        {
            "id": "4564904",
            "type": "article",
            "attributes": {
                "publishOn": "2022-12-16T08:42:12-05:00",
                "isLockedPro": false,
                "commentCount": 55,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1413771624/image_1413771624.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer Talks Up Its Pipeline",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "40031",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "426331",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4564904-pfizer-pipeline-expected-product-launches"
            }
        },
        {
            "id": "4563937",
            "type": "article",
            "attributes": {
                "publishOn": "2022-12-12T11:22:35-05:00",
                "isLockedPro": false,
                "commentCount": 68,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1344323367/image_1344323367.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: The Best Long-Term Investment Setup Since 2009",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "56142",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "425316",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4563937-pfizer-the-best-long-term-investment-setup-since-2009"
            }
        },
        {
            "id": "4563622",
            "type": "article",
            "attributes": {
                "publishOn": "2022-12-10T10:00:00-05:00",
                "isLockedPro": false,
                "commentCount": 4,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Stocks To Watch: Eyes On Pfizer, Yum Brands, Oracle And Centene",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "68015",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4563622-stock-to-watch-eyes-on-pfizer-yum-brands-oracle-and-centene"
            }
        },
        {
            "id": "4561256",
            "type": "article",
            "attributes": {
                "publishOn": "2022-11-29T20:53:44-05:00",
                "isLockedPro": false,
                "commentCount": 171,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1391123438/image_1391123438.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: COVID-19 May Never End",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106297",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "423148",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4561256-pfizer-stock-covid-19-may-never-end"
            }
        },
        {
            "id": "4557407",
            "type": "article",
            "attributes": {
                "publishOn": "2022-11-14T10:00:28-05:00",
                "isLockedPro": false,
                "commentCount": 16,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1344323398/image_1344323398.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: Get Ready To Go On Board",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106173",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "420201",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4557407-pfizer-get-ready-to-go-on-board"
            }
        },
        {
            "id": "4552680",
            "type": "article",
            "attributes": {
                "publishOn": "2022-11-03T14:17:18-04:00",
                "isLockedPro": false,
                "commentCount": 10,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1287045622/image_1287045622.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: Q3 Earnings Review - Planning For Life After COVID",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104985",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "418299",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4552680-pfizer-q3-earnings-review-planning-life-after-covid"
            }
        },
        {
            "id": "4550419",
            "type": "article",
            "attributes": {
                "publishOn": "2022-10-29T08:30:00-04:00",
                "isLockedPro": false,
                "commentCount": 6,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Stocks To Watch: Investors Strap In For FOMC, Jobs Day, Amazon Blowback And Election Trades",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "68015",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4550419-stocks-to-watch-investors-strap-in-for-fomc-jobs-day-amazon-blowback-and-election-trades"
            }
        },
        {
            "id": "4546693",
            "type": "article",
            "attributes": {
                "publishOn": "2022-10-14T21:53:44-04:00",
                "isLockedPro": false,
                "commentCount": 7,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1235266661/image_1235266661.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "The Importance Of Government Contracting For Pfizer And Moderna",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106308",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "414507",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4546693-importance-government-contracting-pfizer-moderna"
            }
        },
        {
            "id": "4545843",
            "type": "article",
            "attributes": {
                "publishOn": "2022-10-11T06:26:33-04:00",
                "isLockedPro": false,
                "commentCount": 21,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1297428013/image_1297428013.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: Bear Market Conviction Pick",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "49201",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "413696",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4545843-pfizer-bear-market-conviction-pick"
            }
        },
        {
            "id": "4542188",
            "type": "article",
            "attributes": {
                "publishOn": "2022-09-20T23:24:20-04:00",
                "isLockedPro": false,
                "commentCount": 31,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1407371840/image_1407371840.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: Do Not Underestimate The Paxlovid Revenues",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106446",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "410081",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4542188-pfizer-pfe-stock-not-underestimate-paxlovid-revenues"
            }
        },
        {
            "id": "4542053",
            "type": "article",
            "attributes": {
                "publishOn": "2022-09-20T10:49:52-04:00",
                "isLockedPro": false,
                "commentCount": 38,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1337208274/image_1337208274.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Myovant: Overvalued Despite Compelling Results From MYFEMBREE",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106075",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "409938",
                            "type": "sentiment"
                        },
                        {
                            "id": "409939",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4542053-women-can-thank-pfizer-and-myovant-for-myfembree"
            }
        },
        {
            "id": "4542038",
            "type": "article",
            "attributes": {
                "publishOn": "2022-09-20T10:04:38-04:00",
                "isLockedPro": false,
                "commentCount": 7,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1354171846/image_1354171846.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: Covid-19 Treatment Isn't Only Expansion Opportunity On Deck",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "58061",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "409959",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4542038-pfizer-covid-19-treatment-isnt-only-expansion-opportunity-on-deck"
            }
        },
        {
            "id": "4541906",
            "type": "article",
            "attributes": {
                "publishOn": "2022-09-19T15:11:43-04:00",
                "isLockedPro": false,
                "commentCount": 14,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1341266246/image_1341266246.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer As A Recession Play",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106277",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "409805",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4541906-pfizer-as-a-recession-play"
            }
        },
        {
            "id": "4541785",
            "type": "article",
            "attributes": {
                "publishOn": "2022-09-19T07:30:00-04:00",
                "isLockedPro": false,
                "commentCount": 176,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1367511149/image_1367511149.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Better High-Yield Pick: AbbVie Vs. Pfizer",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "68315",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "409831",
                            "type": "sentiment"
                        },
                        {
                            "id": "409832",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4541785-abbvie-vs-pfizer-better-high-yield-pick-"
            }
        },
        {
            "id": "4541465",
            "type": "article",
            "attributes": {
                "publishOn": "2022-09-16T12:41:57-04:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1257429592/image_1257429592.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Global Blood Therapeutics: Pfizer Acquisition Signals Increasing M/A Deals",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "56582",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "409509",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4541465-gbt-the-pfizer-acquisition-signals-increasing-ma-deals"
            }
        },
        {
            "id": "4535854",
            "type": "article",
            "attributes": {
                "publishOn": "2022-08-19T17:48:01-04:00",
                "isLockedPro": false,
                "commentCount": 39,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1414273580/image_1414273580.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie Vs. Pfizer: Impact Of The Inflation Reduction Act On Their Future",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106297",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "388613",
                            "type": "sentiment"
                        },
                        {
                            "id": "388614",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4535854-abbvie-vs-pfizer-impact-of-the-inflation-reduction-act-on-their-future"
            }
        },
        {
            "id": "4535160",
            "type": "article",
            "attributes": {
                "publishOn": "2022-08-17T10:17:21-04:00",
                "isLockedPro": false,
                "commentCount": 5,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1323562230/image_1323562230.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: Deal For Global Blood Therapeutics Carries Risk - More M&A Is Needed",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104985",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "388182",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4535160-pfizer-global-blood-therapeutics-deal-carries-risk"
            }
        },
        {
            "id": "4533008",
            "type": "article",
            "attributes": {
                "publishOn": "2022-08-11T12:50:02-04:00",
                "isLockedPro": false,
                "commentCount": 20,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1341266246/image_1341266246.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer Is A Solid High-Yielding Idea",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24491",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "387002",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4533008-pfizer-is-solid-high-yielding-idea"
            }
        },
        {
            "id": "4531480",
            "type": "article",
            "attributes": {
                "publishOn": "2022-08-08T12:15:05-04:00",
                "isLockedPro": false,
                "commentCount": 17,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1403479106/image_1403479106.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "What Pfizer Is Getting Through The Acquisition Of Global Blood Therapeutics",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "40031",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "386605",
                            "type": "sentiment"
                        },
                        {
                            "id": "386606",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4531480-what-pfizer-is-getting-through-the-acquisition-of-global-blood-therapeutics"
            }
        },
        {
            "id": "4530520",
            "type": "article",
            "attributes": {
                "publishOn": "2022-08-05T18:56:16-04:00",
                "isLockedPro": false,
                "commentCount": 13,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1326390933/image_1326390933.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer Looks Oversold",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "20102",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "386297",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4530520-pfizer-looks-oversold"
            }
        },
        {
            "id": "4529640",
            "type": "article",
            "attributes": {
                "publishOn": "2022-08-04T10:44:37-04:00",
                "isLockedPro": false,
                "commentCount": 32,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1361590305/image_1361590305.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Is Pfizer Stock A Buy After Strong Earnings? Massive Profits Won't Last",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "68315",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "385939",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4529640-is-pfizer-stock-buy-after-strong-earnings"
            }
        },
        {
            "id": "4529575",
            "type": "article",
            "attributes": {
                "publishOn": "2022-08-04T08:00:09-04:00",
                "isLockedPro": false,
                "commentCount": 15,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1341266246/image_1341266246.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: Don't Buy Now As Growth Could Slow Significantly",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106173",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "385964",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4529575-pfizer-q2-earnings-growth-could-slow-significantly"
            }
        },
        {
            "id": "4522538",
            "type": "article",
            "attributes": {
                "publishOn": "2022-07-09T23:44:10-04:00",
                "isLockedPro": false,
                "commentCount": 36,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1309776504/image_1309776504.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: New Potential Billion-Dollar Drugs Under Development",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106075",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "381646",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4522538-pfizer-new-potential-billion-dollar-drugs-under-development"
            }
        },
        {
            "id": "4521662",
            "type": "article",
            "attributes": {
                "publishOn": "2022-07-04T13:12:45-04:00",
                "isLockedPro": false,
                "commentCount": 28,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/108219872/image_108219872.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Eli Lilly's Market Cap Is Higher Than Pfizer's - This Anomaly Won't Last",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104985",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "381219",
                            "type": "sentiment"
                        },
                        {
                            "id": "381220",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4521662-eli-lillys-market-cap-is-higher-than-pfizers-this-anomaly-wont-last"
            }
        },
        {
            "id": "4521638",
            "type": "article",
            "attributes": {
                "publishOn": "2022-07-04T08:03:09-04:00",
                "isLockedPro": false,
                "commentCount": 81,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1329618176/image_1329618176.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: In Anticipation Of A New Wave Of COVID-19",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106297",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "381182",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/4521638-pfizer-stock-anticipation-new-wave-covid-19"
            }
        },
        {
            "id": "4520355",
            "type": "article",
            "attributes": {
                "publishOn": "2022-06-26T01:38:18-04:00",
                "isLockedPro": false,
                "commentCount": 25,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1341266246/image_1341266246.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: Well Positioned For Continued Strong Growth",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106331",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "379498",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4520355-pfizer-stock-well-positioned-for-continued-strong-growth"
            }
        },
        {
            "id": "4519594",
            "type": "article",
            "attributes": {
                "publishOn": "2022-06-21T18:31:43-04:00",
                "isLockedPro": false,
                "commentCount": 3,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1257429592/image_1257429592.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Global Blood Therapeutics: Powerhouse Of The Future",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "56582",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "379372",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4519594-global-blood-therapeutics-powerhouse-of-the-future"
            }
        },
        {
            "id": "4518549",
            "type": "article",
            "attributes": {
                "publishOn": "2022-06-15T11:58:15-04:00",
                "isLockedPro": false,
                "commentCount": 10,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1341266246/image_1341266246.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer Will Use Gushes Of Cash To Power Growth",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "102214",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "378390",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4518549-pfizer-will-use-gushes-of-cash-to-power-growth"
            }
        },
        {
            "id": "4518371",
            "type": "article",
            "attributes": {
                "publishOn": "2022-06-14T15:23:46-04:00",
                "isLockedPro": false,
                "commentCount": 13,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1341266246/image_1341266246.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: The Pain Might Not Be Over",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106173",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "378385",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4518371-pfizer-pfe-pain-might-not-be-over"
            }
        },
        {
            "id": "4513633",
            "type": "article",
            "attributes": {
                "publishOn": "2022-05-22T03:15:44-04:00",
                "isLockedPro": false,
                "commentCount": 18,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1324348066/image_1324348066.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: Management's M&A Activity Is Winning Me Over",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104985",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "375041",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4513633-pfizer-managements-m-and-a-activity-is-winning-me-over"
            }
        },
        {
            "id": "4511755",
            "type": "article",
            "attributes": {
                "publishOn": "2022-05-15T08:20:25-04:00",
                "isLockedPro": false,
                "commentCount": 31,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1341266246/image_1341266246.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: Vaccine Has Provided A Long-Term Boost",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25120",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "373984",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4511755-pfizer-vaccine-long-term-boost"
            }
        },
        {
            "id": "4505506",
            "type": "article",
            "attributes": {
                "publishOn": "2022-04-30T09:55:57-04:00",
                "isLockedPro": false,
                "commentCount": 6,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Stocks To Watch: Starbucks, AMD And DraftKings Lead Earnings Parade",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "68015",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4505506-stocks-to-watch-starbucks-amd-and-draftkings-lead-earnings-parade"
            }
        },
        {
            "id": "4502749",
            "type": "article",
            "attributes": {
                "publishOn": "2022-04-21T15:15:14-04:00",
                "isLockedPro": false,
                "commentCount": 21,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1292440985/image_1292440985.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: A Portfolio Prescription For Inflation Investing",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103866",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "370609",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4502749-pfizer-a-portfolio-prescription-for-inflation-investing"
            }
        },
        {
            "id": "4501141",
            "type": "article",
            "attributes": {
                "publishOn": "2022-04-13T06:58:49-04:00",
                "isLockedPro": false,
                "commentCount": 19,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1293330778/image_1293330778.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer's Vaccine-Plus-Treatment Strategy For RSV",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "71185",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "369567",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4501141-pfizer-stock-vaccine-plus-treatment-strategy-rsv"
            }
        },
        {
            "id": "4501041",
            "type": "article",
            "attributes": {
                "publishOn": "2022-04-12T15:18:38-04:00",
                "isLockedPro": false,
                "commentCount": 8,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1293628812/image_1293628812.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Global Blood Therapeutics: Hitting A Growth Inflection",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "56582",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "369481",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4501041-gbt-hitting-a-growth-inflection"
            }
        },
        {
            "id": "4499173",
            "type": "article",
            "attributes": {
                "publishOn": "2022-04-01T00:24:43-04:00",
                "isLockedPro": false,
                "commentCount": 69,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1292440985/image_1292440985.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: How It Could Double",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106337",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "367965",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4499173-pfizer-how-it-could-double"
            }
        },
        {
            "id": "4498801",
            "type": "article",
            "attributes": {
                "publishOn": "2022-03-31T08:30:00-04:00",
                "isLockedPro": false,
                "commentCount": 24,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1235266661/image_1235266661.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: How Will A Fourth COVID Vaccine Shot Impact Stock Outlook?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "71185",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "367682",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4498801-pfizer-fourth-covid-vaccine-shot-impact-stock-outlook"
            }
        },
        {
            "id": "4497821",
            "type": "article",
            "attributes": {
                "publishOn": "2022-03-25T13:36:50-04:00",
                "isLockedPro": false,
                "commentCount": 30,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/484170007/image_484170007.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: Revenues May Reach $100bn In 2022, But The Halo May Be Slipping",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104985",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "367079",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4497821-pfizer-the-halo-may-be-slipping"
            }
        },
        {
            "id": "4495711",
            "type": "article",
            "attributes": {
                "publishOn": "2022-03-15T15:32:57-04:00",
                "isLockedPro": false,
                "commentCount": 23,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1229555002/image_1229555002.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: Strong And Stable Profit Drivers",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106207",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "365472",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4495711-pfizer-strong-and-stable-profit-drivers"
            }
        },
        {
            "id": "4495474",
            "type": "article",
            "attributes": {
                "publishOn": "2022-03-14T23:48:32-04:00",
                "isLockedPro": false,
                "commentCount": 16,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1292440976/image_1292440976.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: The COVID-19 Game Is Not Over Yet - In The Buy Zone",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106173",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "365543",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4495474-pfizer-stock-covid-19-not-over-buy-zone"
            }
        },
        {
            "id": "4495052",
            "type": "article",
            "attributes": {
                "publishOn": "2022-03-12T01:46:18-05:00",
                "isLockedPro": false,
                "commentCount": 4,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1290219676/image_1290219676.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Global Blood Therapeutics: Changing My Strategy After Recent Earnings",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104805",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "365228",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4495052-global-blood-therapeutics-changing-strategy-after-recent-q4-2021-earnings"
            }
        },
        {
            "id": "4494524",
            "type": "article",
            "attributes": {
                "publishOn": "2022-03-10T15:30:00-05:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1235266661/image_1235266661.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "How To Buy Pfizer Stock",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106355",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4494524-invest-in-pfizer-stock"
            }
        },
        {
            "id": "4486787",
            "type": "article",
            "attributes": {
                "publishOn": "2022-02-14T09:50:37-05:00",
                "isLockedPro": false,
                "commentCount": 31,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1292440976/image_1292440976.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Paxlovid Could Help Pfizer Fight Headwinds In Broader Markets",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "31441",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "361304",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4486787-pfizer-pfe-paxlovid-fight-headwinds-broader-markets"
            }
        },
        {
            "id": "4486437",
            "type": "article",
            "attributes": {
                "publishOn": "2022-02-11T14:37:21-05:00",
                "isLockedPro": false,
                "commentCount": 147,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1301584009/image_1301584009.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer, Likely Next mRNA Based Stock To Tumble",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "93676",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "360868",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4486437-pfizer-likely-mrna-stock-tumble"
            }
        },
        {
            "id": "4485126",
            "type": "article",
            "attributes": {
                "publishOn": "2022-02-08T11:15:31-05:00",
                "isLockedPro": false,
                "commentCount": 32,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1289345741/image_1289345741.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer Vs. Merck: Battle Between The Giants During Pandemic And Beyond",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106485",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "360471",
                            "type": "sentiment"
                        },
                        {
                            "id": "360472",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4485126-pfizer-vs-merck-battle-covid-19-pandemic-beyond"
            }
        },
        {
            "id": "4482914",
            "type": "article",
            "attributes": {
                "publishOn": "2022-01-31T07:38:56-05:00",
                "isLockedPro": false,
                "commentCount": 94,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1229555002/image_1229555002.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: Long COVID And Vaccination",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "71185",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "359460",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/4482914-pfizer-long-covid-vaccination"
            }
        },
        {
            "id": "4480992",
            "type": "article",
            "attributes": {
                "publishOn": "2022-01-22T09:57:59-05:00",
                "isLockedPro": false,
                "commentCount": 13,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Stocks To Watch: FOMC Meeting, Earnings Rush And Testing Times In Crypto",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "68015",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4480992-stocks-to-watch-fomc-meeting-earnings-rush-and-testing-times-in-crypto"
            }
        },
        {
            "id": "4480335",
            "type": "article",
            "attributes": {
                "publishOn": "2022-01-19T11:42:59-05:00",
                "isLockedPro": false,
                "commentCount": 16,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1288604066/image_1288604066.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer's Partnership With Beam Therapeutics About Becoming Global Leader In mRNA/Gene Therapy",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104985",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "357814",
                            "type": "sentiment"
                        },
                        {
                            "id": "357815",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4480335-pfizer-partnership-beam-therapeutics-mrna-gene-therapy"
            }
        },
        {
            "id": "4479536",
            "type": "article",
            "attributes": {
                "publishOn": "2022-01-13T13:00:53-05:00",
                "isLockedPro": false,
                "commentCount": 73,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1303175060/image_1303175060.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer And COVID: The Vaccine And Treatment Opportunities Are Still Underappreciated",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "71185",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "356923",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4479536-pfizer-stock-covid-vaccine-pill-treatment"
            }
        },
        {
            "id": "4478390",
            "type": "article",
            "attributes": {
                "publishOn": "2022-01-07T10:30:00-05:00",
                "isLockedPro": false,
                "commentCount": 19,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1229555002/image_1229555002.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "How Will Pfizer's Covid-19 Pill Approval Impact Their Stock Forecast?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106173",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "355955",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4478390-pfizer-covid-19-pill-approval"
            }
        },
        {
            "id": "4478274",
            "type": "article",
            "attributes": {
                "publishOn": "2022-01-06T13:40:46-05:00",
                "isLockedPro": false,
                "commentCount": 19,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1287045622/image_1287045622.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer's Codex DNA Deal Hints At Lucrative Pivot To mRNA - Keep An Eye On This Space",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104985",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "355978",
                            "type": "sentiment"
                        },
                        {
                            "id": "355979",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4478274-pfizers-codex-dna-deal-hints-at-lucrative-pivot-to-mrna-keep-an-eye-on-this-space"
            }
        }
    ]
}